Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Analysts

Dianthus Therapeutics, Inc. ( NASDAQ:DNTH – Get Free Report ) has received an average recommendation of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company.

The average 1 year price target among brokers that have issued ratings on the stock in the last year is $46.43. DNTH has been the subject of a number of analyst reports.



Oppenheimer boosted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th.

HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Raymond James lifted their price objective on Dianthus Therapeutics from $51.

00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Finally, Wedbush dropped their target price on Dianthus Therapeutics from $38.

00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Read Our Latest Report on DNTH Hedge Funds Weigh In On Dianthus Therapeutics Dianthus Therapeutics Stock Performance Dianthus Therapeutics stock opened at $23.

99 on Monday. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.

77. The company has a market capitalization of $710.10 million, a price-to-earnings ratio of -9.

60 and a beta of 1.84. The stock has a fifty day moving average of $26.

66 and a two-hundred day moving average of $26.54. Dianthus Therapeutics ( NASDAQ:DNTH – Get Free Report ) last posted its quarterly earnings data on Thursday, November 7th.

The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.

15). The company had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.

07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.

32%. On average, analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics ( Get Free Report Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Featured Stories Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.

com's FREE daily email newsletter ..